Louise Chen
Stock Analyst at Cantor Fitzgerald
(3.35)
# 1,094
Out of 4,413 analysts
174
Total ratings
44.97%
Success rate
2.93%
Average return
Main Sectors:
38 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Reiterates: Overweight | $815 → $885 | $781.10 | +13.30% | 29 | Apr 30, 2024 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $11.98 | - | 4 | Apr 25, 2024 | |
| PFE Pfizer | Reiterates: Overweight | $45 | $25.62 | +75.64% | 18 | Apr 18, 2024 | |
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $128.31 | +24.70% | 10 | Apr 18, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $135 | $129.22 | +4.47% | 19 | Apr 18, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $144.59 | +48.70% | 24 | Apr 17, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $925 | $890.66 | +3.86% | 1 | Apr 15, 2024 | |
| SPRO Spero Therapeutics | Reiterates: Overweight | n/a | $1.42 | - | 2 | Apr 4, 2024 | |
| SCYX SCYNEXIS | Reiterates: Overweight | n/a | $1.69 | - | 3 | Apr 1, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $4.58 | - | 1 | Apr 1, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Overweight | $65 | $21.52 | +202.04% | 1 | Jan 31, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Neutral | n/a | $1.21 | - | 4 | Nov 14, 2023 | |
| ANL Adlai Nortye | Initiates: Overweight | $30 | $13.80 | +117.39% | 1 | Oct 24, 2023 | |
| IMVT Immunovant | Maintains: Overweight | $30 → $45 | $27.44 | +63.99% | 5 | Oct 16, 2023 | |
| ZLAB Zai Lab | Reiterates: Overweight | $70 | $15.80 | +343.04% | 3 | Oct 9, 2023 | |
| MESO Mesoblast | Reiterates: Overweight | $68 | $6.60 | +930.30% | 3 | Sep 21, 2023 | |
| ROIV Roivant Sciences | Reiterates: Overweight | $15 | $10.90 | +37.61% | 6 | Sep 18, 2023 | |
| CNTB Connect Biopharma Holdings | Reiterates: Overweight | $5 | $1.39 | +259.71% | 2 | Sep 13, 2023 | |
| ATOS Atossa Therapeutics | Initiates: Overweight | $5 | $1.51 | +231.13% | 1 | Sep 8, 2023 | |
| IMAB I-Mab | Reiterates: Overweight | $25 | $1.77 | +1,312.43% | 4 | Sep 5, 2023 | |
| HCM HUTCHMED (China) | Reiterates: Overweight | $50 | $18.51 | +170.12% | 3 | Sep 5, 2023 | |
| ARDX Ardelyx | Upgrades: Overweight | $5 → $10 | $6.40 | +56.25% | 3 | Aug 25, 2023 | |
| PCVX Vaxcyte | Reiterates: Overweight | $70 | $60.55 | +15.61% | 3 | Aug 22, 2023 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Overweight | $50 | $8.32 | +500.96% | 3 | Aug 22, 2023 | |
| TXMD TherapeuticsMD | Reiterates: Neutral | $5 | $1.88 | +165.96% | 4 | Aug 17, 2023 | |
| VYNE VYNE Therapeutics | Maintains: Overweight | $5 → $9 | $2.52 | +257.14% | 1 | May 12, 2023 | |
| CUTR Cutera | Maintains: Neutral | $33 → $21 | $2.42 | +767.77% | 3 | May 10, 2023 | |
| LYRA Lyra Therapeutics | Initiates: Overweight | $15 | $5.16 | +190.70% | 1 | May 24, 2022 | |
| EFTR eFFECTOR Therapeutics | Initiates: Overweight | $1,250 | $2.25 | +55,455.56% | 1 | Sep 13, 2021 | |
| JAGX Jaguar Health | Initiates: Overweight | n/a | $0.21 | - | 1 | Jul 7, 2021 | |
| PDSB PDS Biotechnology | Initiates: Overweight | n/a | $3.35 | - | 1 | Jun 28, 2021 | |
| FDS FactSet Research Systems | Maintains: Neutral | n/a | $416.89 | - | 1 | Mar 27, 2020 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | n/a | $14.05 | - | 2 | Feb 12, 2020 | |
| HRTX Heron Therapeutics | Maintains: Overweight | n/a | $2.32 | - | 1 | Jul 19, 2018 | |
| EOLS Evolus | Maintains: Overweight | n/a | $11.77 | - | 1 | Jun 13, 2018 | |
| OPK OPKO Health | Initiates: Overweight | n/a | $1.22 | - | 2 | Aug 18, 2017 | |
| RVNC Revance Therapeutics | Initiates: Overweight | n/a | $3.61 | - | 1 | Jul 21, 2017 | |
| DERM Journey Medical | Initiates: Overweight | n/a | $3.69 | - | 1 | Jun 22, 2017 |
Eli Lilly
Apr 30, 2024
Reiterates: Overweight
Price Target: $815 → $885
Current: $781.10
Upside: +13.30%
Cidara Therapeutics
Apr 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.98
Upside: -
Pfizer
Apr 18, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.62
Upside: +75.64%
Novo Nordisk
Apr 18, 2024
Reiterates: Overweight
Price Target: $160
Current: $128.31
Upside: +24.70%
Merck & Co.
Apr 18, 2024
Reiterates: Overweight
Price Target: $135
Current: $129.22
Upside: +4.47%
Johnson & Johnson
Apr 17, 2024
Reiterates: Overweight
Price Target: $215
Current: $144.59
Upside: +48.70%
Regeneron Pharmaceuticals
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $890.66
Upside: +3.86%
Spero Therapeutics
Apr 4, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.42
Upside: -
SCYNEXIS
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.69
Upside: -
Zevra Therapeutics
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.58
Upside: -
Rocket Pharmaceuticals
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $21.52
Upside: +202.04%
Aclaris Therapeutics
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Adlai Nortye
Oct 24, 2023
Initiates: Overweight
Price Target: $30
Current: $13.80
Upside: +117.39%
Immunovant
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $45
Current: $27.44
Upside: +63.99%
Zai Lab
Oct 9, 2023
Reiterates: Overweight
Price Target: $70
Current: $15.80
Upside: +343.04%
Mesoblast
Sep 21, 2023
Reiterates: Overweight
Price Target: $68
Current: $6.60
Upside: +930.30%
Roivant Sciences
Sep 18, 2023
Reiterates: Overweight
Price Target: $15
Current: $10.90
Upside: +37.61%
Connect Biopharma Holdings
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.39
Upside: +259.71%
Atossa Therapeutics
Sep 8, 2023
Initiates: Overweight
Price Target: $5
Current: $1.51
Upside: +231.13%
I-Mab
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $1.77
Upside: +1,312.43%
HUTCHMED (China)
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $18.51
Upside: +170.12%
Ardelyx
Aug 25, 2023
Upgrades: Overweight
Price Target: $5 → $10
Current: $6.40
Upside: +56.25%
Vaxcyte
Aug 22, 2023
Reiterates: Overweight
Price Target: $70
Current: $60.55
Upside: +15.61%
Arcutis Biotherapeutics
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $8.32
Upside: +500.96%
TherapeuticsMD
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.88
Upside: +165.96%
VYNE Therapeutics
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $2.52
Upside: +257.14%
Cutera
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $2.42
Upside: +767.77%
Lyra Therapeutics
May 24, 2022
Initiates: Overweight
Price Target: $15
Current: $5.16
Upside: +190.70%
eFFECTOR Therapeutics
Sep 13, 2021
Initiates: Overweight
Price Target: $1,250
Current: $2.25
Upside: +55,455.56%
Jaguar Health
Jul 7, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.21
Upside: -
PDS Biotechnology
Jun 28, 2021
Initiates: Overweight
Price Target: n/a
Current: $3.35
Upside: -
FactSet Research Systems
Mar 27, 2020
Maintains: Neutral
Price Target: n/a
Current: $416.89
Upside: -
Teva Pharmaceutical
Feb 12, 2020
Maintains: Neutral
Price Target: n/a
Current: $14.05
Upside: -
Heron Therapeutics
Jul 19, 2018
Maintains: Overweight
Price Target: n/a
Current: $2.32
Upside: -
Evolus
Jun 13, 2018
Maintains: Overweight
Price Target: n/a
Current: $11.77
Upside: -
OPKO Health
Aug 18, 2017
Initiates: Overweight
Price Target: n/a
Current: $1.22
Upside: -
Revance Therapeutics
Jul 21, 2017
Initiates: Overweight
Price Target: n/a
Current: $3.61
Upside: -
Journey Medical
Jun 22, 2017
Initiates: Overweight
Price Target: n/a
Current: $3.69
Upside: -